Open AccessTaxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer
Author(s) -
Elisabeth Bergen,
Anna S. Berghoff,
Margaretha Rudas,
Peter Dubsky,
Catharina De Vries,
Claudia Sattlberger,
Robert M. Mader,
Flora Zagouri,
Cornelia Sparber,
Florian Fitzal,
Michael Gnant,
Andrea Rottenfusser,
Christoph Zielinski,
Matthias Preusser,
Guenther G. Steger,
Rupert Bartsch
Publication year - 2014
Publication title -
breast care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.767
H-Index - 30
eISSN - 1661-3805
pISSN - 1661-3791
DOI - 10.1159/000368330
Subject(s) - trastuzumab , medicine , vinorelbine , metastatic breast cancer , oncology , breast cancer , cancer , chemotherapy , cisplatin
This retrospective analysis was planned as a direct comparison of taxanes plus trastuzumab to the less toxic combination of oral vinorelbine (OV) plus trastuzumab as a first-line therapy for metastatic HER2-positive breast cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom